E. Clarke Ross, CEO of the patient advocate organization Children and Adults with Adult Deficit/Hyperactivity Disorder (CHADD), wrote a rather lame response to a criticism today in a USA Today editorial regarding the Multimodal Treatment Study for Attention Deficit/Hyperactivity Study (MTA) of ritalin versus psychotherapy for the treatment of childhood ADHD,